Does COVID-19 predispose patients to type 1 diabetes mellitus?

The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Pediatric Endocrinology 2022, Vol.31(1), pp.33-37
Hauptverfasser: Ata, Aysun, Jalilova, Arzu, Kırkgöz, Tarık, Işıklar, Hafize, Demir, Günay, Altınok, Yasemin Atik, Özkan, Behzat, Zeytinlioğlu, Ayşin, Darcan, Şükran, Özen, Samim, Gökşen, Damla
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 37
container_issue 1
container_start_page 33
container_title Clinical Pediatric Endocrinology
container_volume 31
creator Ata, Aysun
Jalilova, Arzu
Kırkgöz, Tarık
Işıklar, Hafize
Demir, Günay
Altınok, Yasemin Atik
Özkan, Behzat
Zeytinlioğlu, Ayşin
Darcan, Şükran
Özen, Samim
Gökşen, Damla
description The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.
doi_str_mv 10.1297/cpe.2021-0050
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8713063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618514221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</originalsourceid><addsrcrecordid>eNpVkE1LAzEQhoMoWqtHr7JHL1tnku5HLoq0fkGhF_UasumsRrbdNUmF_ntTW6teksA8vPPmYewMYYBcFpemowEHjilABnush2JYpIXIyn3WA4llmhVCHrFj798BuIQcDtmRyOIb8rzHrsYt-WQ0fXkcpyiTztHM-q71lHQ6WFoEn4Q2CauOEkxmVlcUIj-nprFh6a9P2EGtG0-n27vPnu9un0YP6WR6_zi6maQmAwlphtUQeCZlYTAuhkobbURtYrVaQl2VMjeyJjLlsJAoZAlyVmCkjeZalJXos6tNbres5jQzsZjTjeqcnWu3Uq226v9kYd_Ua_upygIF5CIGXGwDXPuxJB_U3HoTv6EX1C694jmWGQ45x4imG9S41ntH9W4Nglo7V9G5WjtXa-eRP__bbUf_SI7AaAO8-6BfaQdoF6xp6DtOoML1sYv9nb5pp2ghvgCc4pOM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618514221</pqid></control><display><type>article</type><title>Does COVID-19 predispose patients to type 1 diabetes mellitus?</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Ata, Aysun ; Jalilova, Arzu ; Kırkgöz, Tarık ; Işıklar, Hafize ; Demir, Günay ; Altınok, Yasemin Atik ; Özkan, Behzat ; Zeytinlioğlu, Ayşin ; Darcan, Şükran ; Özen, Samim ; Gökşen, Damla</creator><creatorcontrib>Ata, Aysun ; Jalilova, Arzu ; Kırkgöz, Tarık ; Işıklar, Hafize ; Demir, Günay ; Altınok, Yasemin Atik ; Özkan, Behzat ; Zeytinlioğlu, Ayşin ; Darcan, Şükran ; Özen, Samim ; Gökşen, Damla</creatorcontrib><description>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</description><identifier>ISSN: 0918-5739</identifier><identifier>EISSN: 1347-7358</identifier><identifier>DOI: 10.1297/cpe.2021-0050</identifier><identifier>PMID: 35002066</identifier><language>eng</language><publisher>Japan: The Japanese Society for Pediatric Endocrinology</publisher><subject>children ; COVID-19 ; diabetes mellitus ; Original ; type-1</subject><ispartof>Clinical Pediatric Endocrinology, 2022, Vol.31(1), pp.33-37</ispartof><rights>2022 by The Japanese Society for Pediatric Endocrinology</rights><rights>2022©The Japanese Society for Pediatric Endocrinology.</rights><rights>2022©The Japanese Society for Pediatric Endocrinology 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</citedby><cites>FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713063/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713063/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35002066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ata, Aysun</creatorcontrib><creatorcontrib>Jalilova, Arzu</creatorcontrib><creatorcontrib>Kırkgöz, Tarık</creatorcontrib><creatorcontrib>Işıklar, Hafize</creatorcontrib><creatorcontrib>Demir, Günay</creatorcontrib><creatorcontrib>Altınok, Yasemin Atik</creatorcontrib><creatorcontrib>Özkan, Behzat</creatorcontrib><creatorcontrib>Zeytinlioğlu, Ayşin</creatorcontrib><creatorcontrib>Darcan, Şükran</creatorcontrib><creatorcontrib>Özen, Samim</creatorcontrib><creatorcontrib>Gökşen, Damla</creatorcontrib><title>Does COVID-19 predispose patients to type 1 diabetes mellitus?</title><title>Clinical Pediatric Endocrinology</title><addtitle>Clinical Pediatric Endocrinology</addtitle><description>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</description><subject>children</subject><subject>COVID-19</subject><subject>diabetes mellitus</subject><subject>Original</subject><subject>type-1</subject><issn>0918-5739</issn><issn>1347-7358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkE1LAzEQhoMoWqtHr7JHL1tnku5HLoq0fkGhF_UasumsRrbdNUmF_ntTW6teksA8vPPmYewMYYBcFpemowEHjilABnush2JYpIXIyn3WA4llmhVCHrFj798BuIQcDtmRyOIb8rzHrsYt-WQ0fXkcpyiTztHM-q71lHQ6WFoEn4Q2CauOEkxmVlcUIj-nprFh6a9P2EGtG0-n27vPnu9un0YP6WR6_zi6maQmAwlphtUQeCZlYTAuhkobbURtYrVaQl2VMjeyJjLlsJAoZAlyVmCkjeZalJXos6tNbres5jQzsZjTjeqcnWu3Uq226v9kYd_Ua_upygIF5CIGXGwDXPuxJB_U3HoTv6EX1C694jmWGQ45x4imG9S41ntH9W4Nglo7V9G5WjtXa-eRP__bbUf_SI7AaAO8-6BfaQdoF6xp6DtOoML1sYv9nb5pp2ghvgCc4pOM</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Ata, Aysun</creator><creator>Jalilova, Arzu</creator><creator>Kırkgöz, Tarık</creator><creator>Işıklar, Hafize</creator><creator>Demir, Günay</creator><creator>Altınok, Yasemin Atik</creator><creator>Özkan, Behzat</creator><creator>Zeytinlioğlu, Ayşin</creator><creator>Darcan, Şükran</creator><creator>Özen, Samim</creator><creator>Gökşen, Damla</creator><general>The Japanese Society for Pediatric Endocrinology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2022</creationdate><title>Does COVID-19 predispose patients to type 1 diabetes mellitus?</title><author>Ata, Aysun ; Jalilova, Arzu ; Kırkgöz, Tarık ; Işıklar, Hafize ; Demir, Günay ; Altınok, Yasemin Atik ; Özkan, Behzat ; Zeytinlioğlu, Ayşin ; Darcan, Şükran ; Özen, Samim ; Gökşen, Damla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>children</topic><topic>COVID-19</topic><topic>diabetes mellitus</topic><topic>Original</topic><topic>type-1</topic><toplevel>online_resources</toplevel><creatorcontrib>Ata, Aysun</creatorcontrib><creatorcontrib>Jalilova, Arzu</creatorcontrib><creatorcontrib>Kırkgöz, Tarık</creatorcontrib><creatorcontrib>Işıklar, Hafize</creatorcontrib><creatorcontrib>Demir, Günay</creatorcontrib><creatorcontrib>Altınok, Yasemin Atik</creatorcontrib><creatorcontrib>Özkan, Behzat</creatorcontrib><creatorcontrib>Zeytinlioğlu, Ayşin</creatorcontrib><creatorcontrib>Darcan, Şükran</creatorcontrib><creatorcontrib>Özen, Samim</creatorcontrib><creatorcontrib>Gökşen, Damla</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Pediatric Endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ata, Aysun</au><au>Jalilova, Arzu</au><au>Kırkgöz, Tarık</au><au>Işıklar, Hafize</au><au>Demir, Günay</au><au>Altınok, Yasemin Atik</au><au>Özkan, Behzat</au><au>Zeytinlioğlu, Ayşin</au><au>Darcan, Şükran</au><au>Özen, Samim</au><au>Gökşen, Damla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does COVID-19 predispose patients to type 1 diabetes mellitus?</atitle><jtitle>Clinical Pediatric Endocrinology</jtitle><addtitle>Clinical Pediatric Endocrinology</addtitle><date>2022</date><risdate>2022</risdate><volume>31</volume><issue>1</issue><spage>33</spage><epage>37</epage><pages>33-37</pages><artnum>2021-0050</artnum><issn>0918-5739</issn><eissn>1347-7358</eissn><abstract>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</abstract><cop>Japan</cop><pub>The Japanese Society for Pediatric Endocrinology</pub><pmid>35002066</pmid><doi>10.1297/cpe.2021-0050</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-5739
ispartof Clinical Pediatric Endocrinology, 2022, Vol.31(1), pp.33-37
issn 0918-5739
1347-7358
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8713063
source J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access
subjects children
COVID-19
diabetes mellitus
Original
type-1
title Does COVID-19 predispose patients to type 1 diabetes mellitus?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T16%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20COVID-19%20predispose%20patients%20to%20type%201%20diabetes%20mellitus?&rft.jtitle=Clinical%20Pediatric%20Endocrinology&rft.au=Ata,%20Aysun&rft.date=2022&rft.volume=31&rft.issue=1&rft.spage=33&rft.epage=37&rft.pages=33-37&rft.artnum=2021-0050&rft.issn=0918-5739&rft.eissn=1347-7358&rft_id=info:doi/10.1297/cpe.2021-0050&rft_dat=%3Cproquest_pubme%3E2618514221%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618514221&rft_id=info:pmid/35002066&rfr_iscdi=true